Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2- advanced breast cancer: A phase Ib study.

作者
Qingyuan Zhang,Pin Zhang,Min Yan,Xi Yan,Xian Wang,Yuanting Gu,Xiujuan Qu,Shaorong Li,Guoying Xu,Wenhui Yang,Xiaoyu Zhu,Xiaojing Zhang,Binghe Xu
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): 1066-1066 被引量:1
标识
DOI:10.1200/jco.2022.40.16_suppl.1066
摘要

1066 Background: Dalpiciclib (Dalp; SHR6390) is a novel cyclin-dependent kinase 4/6 inhibitor which showed tolerability and preliminary clinical activity as monotherapy for pretreated advanced breast cancer (ABC). Here we conducted a multicenter, phase 1b trial to further assess the safety, pharmacokinetics and efficacy of Dalp in combination with endocrine therapy (ET) in HR+/HER2- ABC. Methods: 5 cohorts of patients with HR+/HER2- locally recurrent or metastatic BC and any menopausal status were enrolled (~15 patients/combination regimen). Patients without prior treatment for ABC (cohort1/2) were given Dalp (125 or 150 mg po qd, d1-21, q4w) plus letrozole (LTZ; 2.5 mg po qd) or anastrozole (ATZ; 1 mg po qd); patients who progressed after ET (cohort 3-5) were given Dalp (125, 150, or 175 mg po qd, d1-21, q4w) plus fulvestrant (Fulv; 500 mg im, cycle 1 d1, d15, then d1 q4w). The primary endpoint was safety. The data cutoff date was Sep. 20, 2021. Results: 58 patients received Dalp plus LTZ/ATZ and 46 received Dalp plus Fulv. No maximum tolerated dose of Dalp was reached with LTZ/ATZ or Fulv. Across all cohorts, 75.0%-93.8% of patients had a grade ≥3 treatment-related adverse event (TRAE), with the most common being neutropenia (grade 3, 40.0%-87.5%; grade 4, 4.2%-46.7%) and leukopenia (grade 3, 33.3%-80.0%; grade 4, 0%; Table). Treatment-related serious AEs occurred in 2 (3.4%) patients with Dalp plus LTZ/ATZ and none with Dalp plus Fulv. At the tested dose levels, steady-state areas under the concentration curve and peak concentration of Dalp increased with dose in combination with LTZ/ATZ or Fulv. Dalp 150 mg was associated with a numerically higher objective response rate in both ET-untreated (67.6%, 95% CI 49.5-82.6) and ET-pretreated (53.3%, 95% CI 26.6-78.7) patients per investigator. The median progression-free survival with Dalp 150 mg was 20.3 mo (95% CI 16.9-not reached [NR]) and 16.7 mo (95% CI 1.9-24.1) in ET-untreated and ET-pretreated patients respectively. Conclusions: Dalpiciclib plus letrozole/anastrozole or fulvestrant showed an acceptable safety profile, with hematological toxicities as the most common TRAEs. The recommended phase 3 dose of dalpiciclib was 150 mg. Together with the promising anti-tumor activity observed with the combination therapy in HR+/HER2- ABC, further trials are warranted. Clinical trial information: NCT03481998. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
细腻的珩完成签到 ,获得积分10
刚刚
John完成签到,获得积分10
刚刚
123完成签到,获得积分10
刚刚
henkey发布了新的文献求助10
刚刚
走走停停停完成签到,获得积分10
1秒前
1秒前
Yan发布了新的文献求助10
1秒前
万能图书馆的应助被yutu1111采纳,获得10
2秒前
尹丹发布了新的文献求助30
2秒前
2秒前
飞快的孱发布了新的文献求助10
2秒前
后街罗米完成签到,获得积分10
2秒前
晚风完成签到,获得积分10
2秒前
梅川库子完成签到,获得积分10
2秒前
穆礼稀完成签到,获得积分10
3秒前
QDU的应助被dabai采纳,获得20
3秒前
李健的粉丝团团长的应助被gong采纳,获得10
3秒前
Juvenilesy的应助被长青采纳,获得20
3秒前
liney完成签到,获得积分10
3秒前
小包谷完成签到,获得积分10
4秒前
YPHCC发布了新的文献求助10
4秒前
徐臣年完成签到,获得积分10
4秒前
ludong_0完成签到,获得积分10
4秒前
小王完成签到 ,获得积分10
5秒前
852的应助被无忧小姐采纳,获得10
5秒前
自信南霜完成签到 ,获得积分10
5秒前
6秒前
6秒前
6秒前
6秒前
TQZZ完成签到,获得积分20
7秒前
呜呼啦呼完成签到,获得积分10
7秒前
碧蓝幼菱完成签到 ,获得积分10
8秒前
优雅的士萧完成签到,获得积分10
8秒前
十一完成签到,获得积分10
8秒前
耳喃发布了新的文献求助10
8秒前
8秒前
赘婿的应助被元儿采纳,获得30
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105